Determination of Etofibrate, Fenofibrate, and Atorvastatin in Pharmaceutical Preparations and Plasma Using Differential Pulse Polarographic and Square Wave Voltammetric TechniquesKORANY, Mohamed A; HEWALA, Ismail I; ABDEL-HAY, Karim M et al.Journal of AOAC International. 2008, Vol 91, Num 5, pp 1051-1058, issn 1060-3271, 8 p.Article

WIRKUNG EINES NEUEN LIPIDSENKENDEN MEDIKAMENTES BEI HYPERLIPOPROTEINAEMIEN WOM TYP II. I = ACTION D'UN NOUVEL HYPOLIPEMIANT DANS LES HYPERLIPOPROTEINEMIES DE TYPE II. IKNUECHEL F.1974; MED. WELT; DTSCH.; DA. 1974; VOL. 25; NO 43; PP. 1766-1769; BIBL. 6REF.Article

THERAPIE DER HYPERLIPOPROTEINAEMIEN TYP IIA, IIB AND IV MIT ETOFIBRAT RETARD = TRAITEMENT DES HYPERLIPOPROTEINEMIES DE TYPE IIA, IIB ET IV PAR L'ETOFIBRAT RETARDSCHWARTZKOPFF W; SCHILLING A; CALDER D et al.1980; MED. WELT; DEU; DA. 1980; VOL. 31; NO 14; PP. 515-520; BIBL. 62 REF.Article

WIRKUNG EINES NEUEN LIPIDSENKENDEN MEDIKAMENTES (ETOFIBRAT) BEI HYPERLIPOPROTEINAEMIEN VOM TYP II. II = ACTION D'UN NOUVEL HYPOLIPEMIANT (ETOFIBRAT) DANS LES HYPERLIPOPROTEINEMIES DE TYPE II. 2E COMMUNICATIONKNUCHEL F.1974; MED. WELT.; DTSCH.; DA. 1974; VOL. 25; NO 44; PP. 1810-1812; BIBL. 5REF.Article

LANGZEITTHERAPIE MIT ETOFIBRAT = TRAITEMENT A LONG TERME AVEC L'ETOFIBRATEKAFFARNIK H; SCHNEIDER J; SCHUBOTZ R et al.1980; MUENCH. MED. WSCHR.; DEU; DA. 1980; VOL. 122; NO 3; PP. 95-98; ABS. ENG; BIBL. 25 REF.Article

ETOFIBRAT UND CLOFIBRAT IM DOPPELBLINDVERSUCH BEI DER BEHANDLUNG ERHOEHTER SERUM LIPIDE. = ESSAI EN DOUBLE AVEUGLE DE L'ETOFIBRATE ET DU CLOFIBRATE CHEZ DES MALADES AVEC UN TAUX SANGUIN DE LIPIDES TRES ELEVEKAFFARNIK H; SCHNEIDER J; HAASE W et al.1975; DTSCHE MED. WSCHR.; DTSCH.; DA. 1975; VOL. 100; NO 48; PP. 2486-2488; ABS. ANGL.; BIBL. 5 REF.Article

COMPOSIZIONE LIPIDICA BILIARE IN SOGGETTI DISLIPIDEMICI (IIE IV TIPO). EFFETTO DI UN NUOVO FARMACO IPOLIPEMIZZANTE: L'ETOFIBRATO = COMPOSITION DES LIPIDES BILIAIRES CHEZ DES SUJETS ATTEINTS DE DYSLIPIDEMIE DE TYPE II ET IV. EFFET D'UN NOUVEAU MEDICAMENT HYPOLIPEMIANT: L'ETOFIBRATEALTOMONTE L; MINGRONE G; CHIRLANDA G et al.1980; MINERVA MED.; ITA; DA. 1980; VOL. 71; NO 4; PP. 273-278; ABS. ENG; BIBL. 22 REF.Article

ZUR WIRKSAMKEIT VON ETOFIBRAT BEI DEN HYPERLIPOPROTEINAEMIETYPEN IIA, IIB UND IV: VERGLEICHSSTUDIE ZU CLOFIBRAT = ACTIVITE DE L'ETOFIBRATE DANS LES TYPES IIA IIB ET IV D'HYPERLIPOPROTEINEMIE ETUDE COMPARATIVE AVEC LE CLOFIBRATESCHWARTZKOPFF W; ZSCHIEDRICH M; RAHLFS VW et al.1980; THERAPIEWOCHE; DEU; DA. 1980; VOL. 30; NO 21; PP. 3805-3814; (8 P.); ABS. ENG; BIBL. 74 REF.Article

ZUR WIRKUNG VON ETOFIBRAT AUF CHOLESTERIN- UND TRIGLYCERIDWERTE IM SERUM = L'ACTION DE L'ETOFIBRATE SUR LES TAUX SERIQUES DE CHOLESTEROL ET DE TRIGLYCERIDESDIMROTH H.1979; MED. KLIN.; DEU; DA. 1979; VOL. 74; NO 22; PP. 875-876; ABS. ENG; BIBL. 10 REF.Article

VERGLEICHENDE UNTERSUCHUNGEN ZUR WIRKSAMKEIT VON ETOFIBRAT RETARD UND FENOFIBRAT BEI HYPERLIPOPROTEINAEMIE = ETUDES COMPARATIVES SUR L'EFFICACITE DE L'ETOFIBRATE RETARD ET DU FENOFIBRATE DANS L'HYPERLIPOPROTEINEMIESCHWARTZKOPFF W; SCHILLING A.1980; MED. WELT; ISSN 0025-8512; DEU; DA. 1980; VOL. 31; NO 50; PP. 1845-1851; BIBL. 52 REF.Article

DER EINFLUSS VON ETOFIBRAT AUF DIE PLASMAVISKOSITAET BEI HYPERLIPOPROTEINAEMIEN. = INFLUENCE DE L'ETOFIBRATE SUR LA VISCOSITE DU PLASMA DANS LES HYPERLIPOPROTEINEMIEPFEIFFER M; TILSNER V.1978; MED. KLIN.; DTSCH.; DA. 1978; VOL. 73; NO 2; PP. 60-62; ABS. ANGL.; BIBL. 8 REF.Article

Hemostatic factors in hypertriglyceridemic men : Effects of a fatty meal before and after triglyceride-lowering treatment with etofibrateORTH, M; MAYER, H; HALLE, M et al.Thrombosis research. 1999, Vol 94, Num 6, pp 341-351, issn 0049-3848Article

PREDICTION OF STABILITY IN PHARMACEUTICAL PREPARATIONS. XIX: STABILITY EVALUATION AND BIOANALYSIS OF CLOFIBRIC ACID ESTERS BY HIGH-PRESSURE LIQUID CHROMATOGRAPHYGARRETT ER; GARDNER MR.1982; J. PHARM. SCI.; ISSN 0022-3549; USA; DA. 1982; VOL. 71; NO 1; PP. 14-25; BIBL. 18 REF.Article

THERAPIE DER HYPERLIPOPROTEINAEMIE. VERGLEICH ZWISCHEN LIPO-MERZ RETARD UND EINEM HANDELSUEBLICHEN KOMBINATIONSPRAEPARAT = TRAITEMENT DE L'HYPERLIPOPROTEINEMIE. COMPARAISON ENTRE LE LISO-MERZ RETARD ET UNE PREPARATION ASSOCIEE COMMERCIALESTEGER W.1980; FORTSCHR. D. MED.; DEU; DA. 1980; VOL. 98; NO 18; PP. 718-720; BIBL. 7 REF.Article

ALTERNATIVE IN DER THERAPIE PRIMAERER HYPERLIPIDAEMIEN: ETOFIBRAT IN RETARDFORM = ALTERNATIVE DANS LE TRAITEMENT DES HYPERLIPEMIES PRIMAIRES: ETOFIBRATE SOUS FORME RETARDFUSGEN I; SUMMA JD.1980; MED. KLIN. (MUENCHEN); ISSN 0025-8458; DEU; DA. 1980; VOL. 75; NO 23; PP. 43-45; BIBL. 10 REF.Article

ZUR STABILITAET DES BLUTLIPIDSENKERS ETOFIBRAT UND SEINER METABOLITE GEGENUEBER HYDROLASEN DES GASTRAINTESTINALTRAKTES UND DES BLUTES. II: ZUR PHARMAKOKINETIK VON LIPIDSENKERN = LA STABILITE DE L'ETOFIBRATE AGENT HYPOLIPEMIANT ET DE SES METABOLITES ENVERS LES HYDROLASES DU TRACTUS GASTROINTESTINAL ET DU SANG. II. PHARMACOCINETIQUE DES AGENTS HYPOLIPEMIANTSOELSCHLAEGER H; ROTHLEY D; EWERT M et al.1980; ARZNEIMITTEL. FORSCH.; DEU; DA. 1980; VOL. 30; NO 6; PP. 984-988; ABS. ENG; BIBL. 6 REF.Article

Etofibrate treatment alters low density lipoprotein susceptibility to lipid peroxidationWÜLFROTH, P; RICHTER, C. M; BURKARD, M et al.Drugs under experimental and clinical research. 1992, Vol 18, Num 11-12, pp 469-474, issn 0378-6501Article

Concentration of clofibric acid in blood after the administration of delayed-release form of etofibrateVAZQUEZ LOPEZ, F; ARMIJO CASTRO, F; PIRE SOLIS, I et al.International journal of clinical pharmacology, therapy and toxicology (1980). 1987, Vol 25, Num 1, pp 31-35, issn 0174-4879Article

Plasmolysis, red blood cell partitioning, and plasma protein binding of etofibrate, clofibrate, and their degradation productsALTMAYER, P; GARRETT, E. R.Journal of pharmaceutical sciences. 1983, Vol 72, Num 11, pp 1309-1318, issn 0022-3549Article

Mitochondrial myopathy: a result of clofibrate/etofibrate treatment? Case reportBARDOSI, A; SCHEIDT, P; GOEBEL, H. H et al.Acta neuropathologica. 1985, Vol 68, Num 2, pp 164-168, issn 0001-6322Article

FAT METABOLISM, THE FIBRINOGEN/FIBRINOLYTIC SYSTEM AND BLOOD FLOWS: NEW POTENTIALS FOR THE PHARMACOLOGICAL TREATMENT OF CORONARY HEART DISEASEPICKART L.1981; PHARMACOLOGY; ISSN 0031-7012; USA; DA. 1981; VOL. 23; NO 5; PP. 271-280; BIBL. 42 REF.Article

Effect of niacin and etofibrate association on subject with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dlSPOSITO, A. C; CARAMELLI, B; SERRANO, C. V et al.The American journal of cardiology. 1999, Vol 83, Num 1, pp 98-100, issn 0002-9149Article

Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosisBETZ, E; QUACK, G.VASA. 1990, Vol 19, Num 2, pp 157-160, issn 0301-1526, 4 p.Article

Relative bioavailability of etofibrate: a comparison of an acute and a new sustained release formulationJOHNSON, K. I; HOPPE, H.-J; SCHATTON, W et al.Arzneimittel-Forschung. 1984, Vol 34, Num 12, pp 1785-1787, issn 0004-4172Article

Studies with etofibrate in the rat. II: A comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysisBOCOS, C; CASTRO, M; QUACK, G et al.Biochimica et biophysica acta, L. Lipids and lipid metabolism. 1993, Vol 1168, Num 3, pp 340-347, issn 0005-2760Article